Focuses on addiction treatment therapies, specializing in opioid dependence and related mental health disorders.
Indivior PLC, headquartered in North Chesterfield, Virginia, is a global leader in the development, manufacturing, and distribution of buprenorphine-based prescription drugs. These medications are primarily aimed at treating opioid dependence and co-occurring disorders across the United States, the United Kingdom, and international markets. Beyond its focus on opioid use disorder, Indivior PLC also develops therapies for substance use disorders and serious mental illnesses, as well as treatments for opioid overdose.
Key products in Indivior's portfolio include SUBLOCADE and SUBUTEX PRO, which are extended-release monthly injections of buprenorphine. The company also offers SUBOXONE, available as both a sublingual film and tablet, combining buprenorphine with naloxone, and SUBUTEX, a buprenorphine sublingual tablet. These products play a critical role in opioid addiction treatment and management.
In addition to its established product line, Indivior PLC is advancing several innovative therapies through its pipeline. These include INDV-2000, a selective orexin-1 receptor antagonist for opioid use disorder, and INDV-1000, a selective GABAb positive allosteric modulator targeting alcohol use disorder. Collaborations with partners like Alar Pharmaceuticals Inc. and Click Therapeutics are focused on developing long-acting injectables and diggital therapeutics for opioid use disorder. Indivior PLC's dedication to advancing addiction medicine underscores its commitment to improving patient outcomes and addressing significant public health challenges globally.